Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1

Area of Science:

• Molecular and Cellular Oncology
• Cancer Immunology
• Drug Discovery

Background:

• Sigma1 (SIGMAR1) is a scaffolding protein involved in cellular homeostasis.
• Programmed death-ligand 1 (PD-L1) suppresses antitumor immunity by inhibiting T cells.
• Modulating Sigma1 affects endoplasmic reticulum-associated protein homeostasis in cancer cells.

Purpose of the Study:

• To investigate the role of Sigma1 in regulating PD-L1 protein levels in cancer cells.
• To determine if Sigma1 modulators can impact PD-L1 expression and function.
• To explore the mechanism by which Sigma1 influences PD-L1 degradation.

Main Methods:

• RNAi knockdown and small-molecule inhibition of Sigma1 in cancer cells.
• Pharmacologic competition assays using Sigma1-selective ligands.
• Analysis of cell surface PD-L1 expression and PD-1/PD-L1 interactions.
• Investigation of PD-L1 degradation pathways, including selective autophagy.

Main Results:

• Sigma1 knockdown and inhibition significantly reduced PD-L1 protein levels in cancer cells.
• Sigma1 inhibitors decreased cell surface PD-L1 and suppressed PD-1/PD-L1 interactions.
• Sigma1 inhibition induced PD-L1 degradation via a mechanism of selective autophagy.
• Sigma1 modulators demonstrated both positive and negative regulation of PD-L1 processing.

Conclusions:

• Small-molecule Sigma1 modulators can effectively reduce PD-L1 expression in cancer cells.
• Sigma1 inhibition promotes PD-L1 degradation through selective autophagy.
• Sigma1 modulators represent a novel therapeutic strategy for PD-L1/PD-1 blockade therapies.